// App-Quantinova.ai

270 : A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Researchers

Presenter

  • Xian Zhang

Principal Investigators

  • Jiasheng Wang

  • Yue Liu

  • Junfang Yang

  • Jingjing Li

  • Gailing Zhang

  • Yanze Shi

  • Jiujiang He

  • Dan Song

  • Wenqian Li

  • Shulian Xia

  • Min Zhang

  • Zhixiao Zhou

  • Lemei Jia

  • Hongli Zheng

  • Xin Lin

  • Peihua Lu

Medical Centers

  • Lu Daopei Institute of Hematology, Beijing, China

  • Hebei Yanda Lu Daopei Hospital, Langfang, China

  • 3. Department of Basic Medical Sciences and Institute for Immunology, Tsinghua University School of Medicine, Beijing, China

  • China Immunotech (Beijing) Biotechnology Co. Ltd.,Beijing,China

  • 3. Department of Basic Medical Sciences and Institute for Immunology, Tsinghua University School of Medicine, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • STAR syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03953599

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved